Ugo De Giorgi

Research interests

Publications

• Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)01055-3

• Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(21)00660-4

• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00487-9

• Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.01.002

• Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2035716

• Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03292

• Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03296

• Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)30230-0

• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30541-6

• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30541-6

• Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

  Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0579-z

• Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)30723-8

• Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-18-3661

• Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-18-0981

• Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)33297-x

• Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.65.5597

• Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1303989

• Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds579

• Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.32.6678

• Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

  Breast Cancer Research · 2011 · https://doi.org/10.1186/bcr2907

• Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group

  Journal of Clinical Oncology · 2001 · https://doi.org/10.1200/jco.2001.19.10.2647

Current projects

No projects listed.